Gain Therapeutics (GANX) Assets (2020 - 2026)

Gain Therapeutics has reported Assets for 7 years, with the latest figure at $15.4 million in Q2 2026.

• On a quarterly basis, Assets rose 56.82% year-over-year to $15.4 million in Q2 2026; TTM through Jun 2026 was $15.4 million, a 56.82% increase from a year earlier, with the FY2025 full-year figure at $22.8 million, up 88.22% from the prior year.
• Assets was $15.4 million for Q2 2026 at Gain Therapeutics, down from $18.7 million in the prior quarter.
• The five-year high for Assets was $37.6 million in Q1 2022, with the low at $9.8 million in Q2 2025.
• Average Assets over 5 years is $19.1 million, with a median of $18.4 million recorded in 2023.
• The sharpest annual moves came in 2023 and 2025: Assets plunged 50.23% in 2023, then jumped 88.22% in 2025.
• Over 5 years, Assets stood at $24.1 million in 2022, then retreated by 22.78% to $18.6 million in 2023, then slumped by 34.85% to $12.1 million in 2024, then surged by 88.22% to $22.8 million in 2025, then plunged by 32.42% to $15.4 million in 2026.
• The last three Assets figures came in at $15.4 million (Q2 2026), $18.7 million (Q1 2026), and $22.8 million (Q4 2025), per Business Quant data.